Integrating Clinical, Protein Expression, and Genetic Markers to Predict Lymphedema in Breast Cancer

Dharmais National Cancer Center Hospital133 enrolled

Overview

The goal of this observational ambidirectional cohort study is to develop a prediction model to identify the risk of lymphedema after axillary lymph node dissection (ALND) in patients with breast cancer. The main questions it aims to answer are: * Can clinicopathological factors predict the development of lymphedema? * Do protein expression profiles and genetic mutations increase susceptibility to lymphedema? Participants will: * Undergo clinical evaluation and indocyanine green (ICG) lymphography to diagnose lymphedema. * Provide lymphatic tissue and blood samples during ALND surgery for immunohistochemical protein analysis and gene mutation assessment. * Be followed over time to monitor the onset and progression of lymphedema.

Study Type

OBSERVATIONAL

Enrollment

133

Conditions

Lymphedema Arm

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years * Histopathologically confirmed breast cancer * Undergoing axillary lymph node dissection (ALND) * Able to undergo indocyanine green (ICG) lymphography examination Exclusion Criteria: * Clinical signs of lymphedema prior to surgery, confirmed by clinical assessment and/or ICG lymphography * History of iodine allergy, asthma, impaired renal function, pregnancy, or breastfeeding * Incomplete clinical or laboratory data required for analysis

Locations (1)

Dharmais Cancer Hospital

Outcomes

Primary Outcomes

Occurrence of Arm Lymphedema

Development of lymphedema identified through clinical signs and symptoms, confirmed using indocyanine green (ICG) lymphography. The presence or absence of lymphedema will be recorded during follow-up assessments.

Time frame: Up to 24 months post-axillary lymph node dissection